XSHE
002737
Market cap984mUSD
Oct 09, Last price
11.53CNY
1D
2.22%
1Q
-7.98%
Jan 2017
-31.55%
IPO
-20.29%
Name
Sunflower Pharmaceutical Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sunflower Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the comprehensive process of traditional Chinese medicine (TCM), covering everything from research and development to production and market distribution within China. The company's product range also extends to include chemical, biological, and health-focused pharmaceuticals. These diverse medications address a broad spectrum of medical needs, providing solutions in areas such as pediatrics, gynecology, digestive system ailments, respiratory issues including the common cold, conditions related to rheumatism and bone health, and cardiovascular and cerebrovascular disorders. The company's goods are sold under its established brands, "Sunflower" and "Little Sunflower." With its headquarters located in Harbin, China, Sunflower Pharmaceutical Group was founded in 2005.
Key people
Yanbin Guan
Chairman of the Board, General Manager · since 2017
Yanhui Zhang
Finance Director, Deputy General Manager · since 2018
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||